Safety of PPAR agonists

Diabetes Care

Volumn 34, Issue SUPPL. 2, 2011, Pages

  Home, Philip ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FATTY ACID; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE; ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ADIPOSE TISSUE; ANKLE EDEMA; ARM FRACTURE; BLADDER CANCER; CANCER RISK; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG MECHANISM; DRUG SAFETY; FLUID RETENTION; FRACTURE; GENOTOXICITY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; LEG FRACTURE; LIPID METABOLISM; LIPID STORAGE; LIVER FUNCTION; META ANALYSIS (TOPIC); MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; STROKE; STUDY DESIGN; ARTICLE; DRUG POTENTIATION;

DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES;

EID: 79959808354     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-s233     Document Type: Review

References (30)

1. Willson TM, Wahli W. Peroxisome proliferator-activated receptor agonists. Curr Opin Chem Biol 1997;1:235-241 (Pubitemid 127437150)
2. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003; 108:2941-2948 (Pubitemid 37517824)
3. Takeda Global Research and Development Centre (Europe) Ltd. Actos: summary of product characteristics [Internet], 2005. Available from http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR---Summary-for-the- public/human/000285/ WC500021379.pdf. Accessed 9 March 2011
4. SmithKline Beecham. Avandia: summary of product characteristics [Internet], 2006. Available from http://www.ema.europa.eu. Accessed 19 June 2007
5. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443 (Pubitemid 44903747)
6. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471 (Pubitemid 46919772)
7. Oleksiewicz MB, Southgate J, Iversen L, Egerod FL. Rat urinary bladder carcinogenesis by dual-acting PPARα + γ agonists. PPAR Res 2008;103167:1-14
8. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn A-R; PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009;32:187-202
9. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G; ADOPT Study Group; RECORD Steering Committee. Experience of malignancies with oral glucose- lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010; 53:1838-1845
10. Takeda Pharmaceuticals North America. Observation of an Increased Incidence of Fractures in Female Patients who Received Long-Term Treatment With Actos (Pioglitazone HCl) Tablets for Type 2 Diabetes Mellitus. Deerfield, IL, Takeda Pharmaceuticals North America, 2007
11. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-851
12. Home PD, Pocock SJ, Beck-Nielsen H, et al. RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373:2125-2135
13. Aubert RE, Herrera V, Chen W, Haffner SM, Pendergrass M. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab 2010;12:716-721
14. Ryan EH Jr, Han DP, Ramsay RC, et al. Diabetic macular edema associated with glitazone use. Retina 2006;26:562-570 (Pubitemid 44620399)
15. Ambrosius WT, Danis RP, Goff DC Jr, et al. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol 2010;128:312-318
16. Dargie HJ, Hildebrandt PR, Riegger GAJ, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 2007;49:1696-1704 (Pubitemid 46589926)
17. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289 (Pubitemid 41416583)
18. Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007;30:2773-2778 (Pubitemid 350083116)
19. Cobitz A, Zambanini A, Sowell M, et al. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone. Pharmacoepidemiol Drug Saf 2008;17:769-781
20. McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007; 16:711-725 (Pubitemid 47180361)
21. Callaghan F. Rosiglitazone cardiovascular safety meta-analysis [Internet]. Available from http://www.fda.gov/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisory Committee/ucm218481.htm. Accessed 13 July 2010
22. Parks MH. Advisory Committee Meeting Avandia (rosiglitazone maleate) 13-14 July 2010 [Internet]. Available from http://www.fda.gov/ AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisory Committee/ucm218481.htm. Accessed 13 July 2010
23. McEvoy B. Pioglitazone and rosiglitazone cardiovascular safety meta-analyses [Internet]. Available from http://www.fda.gov/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm218481.htm. Accessed 13 July 2010
24. Mahoney KM. Topics related to interpretability [Internet]. Available from http:// www.fda.gov/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugs AdvisoryCommittee/ucm218481.htm. Accessed 13 July 2010
25. Laws I, Home PD, Stewart M. Avandia (rosiglitazone maleate): RECORD study [Internet]. Available fromhttp://www.fda. gov/AdvisoryCommittees/Committees MeetingMaterials/Drugs/Endocrinologic andMetabolicDrugsAdvisoryCommittee/ ucm218481.htm. Accessed 13 July 2010
26. Ye J, Yang F, Stewart M. Modification of the UKPDS risk engine to evaluate cardiovascular event rates in controlled clinical trials (Abstract).Diabetes 2010;59(Suppl. 1): 704P
27. Brooks MM. Rosiglitazone use and cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI-2D) trial [Internet]. Available from http://www.fda.gov/ AdvisoryCommittees/CommitteesMeeting Materials/Drugs/Endocrinologicand MetabolicDrugsAdvisoryCommittee/ucm218481.htm. Accessed 13 July 2010
28. Moritz T. Impact of the use of rosiglitazone in the Veterans Affairs Diabetes Trial (VADT) [Internet]. Available from http:// www.fda.gov/ AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugs AdvisoryCommittee/ucm218481.htm. Accessed 13 July 2010
29. Stewart M. Avandia (rosiglitazone maleate) [Internet]. Available from http://www. fda.gov/AdvisoryCommittees/Committees MeetingMaterials/Drugs/ Endocrinologic andMetabolicDrugsAdvisoryCommittee/ ucm218481.htm. Accessed 13 July 2010
30. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304: 411-418